Freestone Grove Partners LP Invests $368,000 in ICU Medical, Inc. (NASDAQ:ICUI)

Freestone Grove Partners LP purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,371 shares of the medical instruments supplier's stock, valued at approximately $368,000.

A number of other hedge funds have also made changes to their positions in ICUI. Northern Trust Corp boosted its position in ICU Medical by 11.1% during the fourth quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier's stock worth $62,431,000 after purchasing an additional 40,187 shares during the period. Quarry LP boosted its stake in ICU Medical by 764.3% during the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 214 shares during the period. Three Seasons Wealth LLC bought a new position in ICU Medical in the 4th quarter worth approximately $291,000. Two Sigma Securities LLC acquired a new position in shares of ICU Medical during the fourth quarter worth approximately $229,000. Finally, Oberweis Asset Management Inc. boosted its position in shares of ICU Medical by 20.1% in the fourth quarter. Oberweis Asset Management Inc. now owns 156,680 shares of the medical instruments supplier's stock valued at $24,312,000 after acquiring an additional 26,180 shares during the period. Institutional investors and hedge funds own 96.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ICUI. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Raymond James set a $97.00 price target on ICU Medical in a research note on Wednesday, March 12th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday, May 2nd. Finally, KeyCorp lowered their price objective on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $162.67.

ICU Medical Price Performance

NASDAQ ICUI traded up $8.15 during trading on Thursday, reaching $142.65. 468,670 shares of the company traded hands, compared to its average volume of 273,683. ICU Medical, Inc. has a 1-year low of $100.69 and a 1-year high of $196.26. The company has a market cap of $3.51 billion, a price-to-earnings ratio of -31.22 and a beta of 0.87. The stock's 50 day moving average price is $140.70 and its two-hundred day moving average price is $155.82. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.